Back to Search
Start Over
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
- Source :
- The Lancet HIV, 9, e638-e648, The Lancet HIV, 9, 9, pp. e638-e648
- Publication Year :
- 2022
-
Abstract
- Contains fulltext : 283099.pdf (Publisher’s version ) (Open Access) BACKGROUND: Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg. METHODS: ODYSSEY is an open-label, randomised, non-inferiority trial (10% margin) comparing dolutegravir-based ART with standard of care and comprises two cohorts (children weighing ≥14 kg and
- Subjects :
- Adult
Epidemiology
Pyridones
Anti-HIV Agents
Immunology
HIV Infections
3-Ring
Piperazines
Heterocyclic Compounds
Virology
Oxazines
Humans
Protease Inhibitors
Child
Preschool
Infant, Newborn
Infant
Bayes Theorem
Viral Load
Newborn
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
Infectious Diseases
Child, Preschool
Heterocyclic Compounds, 3-Ring
Treatment Outcome
Subjects
Details
- ISSN :
- 23523018
- Database :
- OpenAIRE
- Journal :
- The Lancet HIV, 9, e638-e648, The Lancet HIV, 9, 9, pp. e638-e648
- Accession number :
- edsair.doi.dedup.....505a934fdd30e2121208ab0c6bf684d9